Equity Strategy
How Long Before a Vaccine can Restore Earnings?
Thu 19th November, 2020

News of early phase 3 vaccine trial results from both Pfizer and Moderna have, for the first time in 9 months, given the market a visible path out of COVID-19 lockdowns and economic dislocation. While this is undeniably good news from both a health and economic perspective, investors across different sectors in the Australian market have wildly different views around when a vaccine will become effective from an earnings perspective. This week we take a look into the market’s assumptions around the speed of the recovery across different sectors and share how Wilsons is thinking about playing the earnings recovery. We look at:

  • The extent of ‘lost’ earnings
  • Vaccine recovery time frames across different sectors
  • The impact of share dilution
  • Cyclical recovery plays in a portfolio context

    About Wilsons: Wilsons is a financial advisory firm focused on delivering strategic and investment advice for people with ambition – whether they be a private investor, corporate, fund manager or global institution. Its client-first, whole of firm approach allows Wilsons to partner with clients for the long-term and provide the wide range of financial and advisory services they may require throughout their financial future. Wilsons is staff-owned and has offices across Australia.

    Disclaimer: This communication has been prepared by Wilsons Advisory and Stockbroking Limited (ACN 010 529 665: AFSL 238 375) and Wilsons Corporate Finance Limited (ACN 057 547 323: AFSL 238 383) (“Wilsons”), and to the extent that it contains advice, that advice is general in nature and does not consider your personal circumstances.

    The information in this communication does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. Past performance is not a reliable indicator of future performance. On that basis, any advice should not be relied on to make any investment decisions without first consulting with your financial adviser. If you do not currently have an adviser, please contact us and we would be happy to connect you with a Wilsons representative.

    To the extent that any specific documents or products are referred to, please also ensure that you obtain the relevant document or Product Disclosure Statement(s) before considering any related investments.

    Wilsons and their associates may have received and may continue to receive fees from any company or companies referred to in this communication (the “Companies”) in relation to corporate advisory, underwriting or other professional investment services. Please see relevant Wilsons disclosures at www.wilsonsadvisory.com.au/disclosures.

    • Share This Article

    Written by

    John Lockton , Australian Equities

    John is a leading investment strategist with 20 years experience.

    Related articles